PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.

ABSTRACT:

Objective

The aim of this study was to determine the poly (ADP-ribose) polymerase inhibitors (PARPis) response and outcome of ovarian cancer (OC) patients with BRCA1/2 germline mutation and a history of breast cancer (BC).

Methods

Thirty-nine OC patients with BRCA1/2 germline mutation and a history of BC were included. The clinicopathological characteristics, PARPis response and prognosis were analyzed.

Results

The median interval from BC to OC diagnosis was 115.3 months (range=6.4-310.1). A total of 38 patients (38/39, 97.4%) received platinum-based chemotherapy after surgical removal. The majority of these patients were reported to be platinum sensitive (92.1%, 35/38). 21 patients (53.8%) received PARPis treatment with 16 patients (76.2%) for maintenance treatment a

SUBMITTER: Yuan H 

PROVIDER: S-EPMC11262894 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature